Research and Science / Research — Rare Subtypes
Advancing Research for the Rare Melanoma Subtypes
Hosted Meeting CURE OM Global Science Meeting The 14th Annual CURE OM Global Science Meeting was held in the fall of 2025 in conjunction with the Society for Melanoma Congress (SMR). The goal of this meeting is to foster interdisciplinary collaboration and innovation between global leading OM researchers and clinicians, patients and industry partners. A few highlights from the 2025 meeting include: • 60 international OM experts attended • 18 speakers representing the scientific community and industry presented on various topics • Session topics included: – Powering the Immune Arsenal: ICIs, Vaccines, Viruses & Cellular Approaches – Fueling Discovery: Tools Driving OM Research Forward – Innovation Lighting Talks from Industry – T Cell Engagers & the RECIST Disconnect: What Tebe Teaches Us – Targeted Therapy: Assessing Darovasertib- Crizotinib for Optimal Outcomes • Industry sponsors include: Replimune, Immunocore, Castle Biosciences, IDEAYA Biosciences, Aura, Delcath and iOnctura
Spotlighting an Acral and Mucosal Melanoma Career Development Award Transforming Therapy for Acral and Mucosal Melanoma Using RAS(ON) Inhibitors “By identifying the biological mechanisms that allow the cancer to escape treatment, I aim to discover combination therapies that can enhance the effectiveness of RAS(ON) inhibitors. The results of this research will provide valuable insights into how acral and mucosal melanoma can be better treated, guiding the development of new, more effective therapies. Ultimately, this work aims to bring new hope to patients with these rare and challenging melanomas by advancing precision medicine approaches tailored to their unique cancer biology.” Spotlighting a Mucosal Melanoma Resident Fellow Award Molecular Investigation of Metastatic Sinonasal Mucosal Melanoma “Sinonasal mucosal melanoma (SNMM) is a rare primary malignancy with aggressive clinical behavior, affecting the sinonasal tract. Spotlighting a Uveal Melanoma Medical Student Award Multimodal Tumor Measurements for Advancing Uveal Melanoma Diagnostics “Our study aims to combine circulating hybrid cell detection and quantification with cutting-edge clinical imaging to identify uveal patients at increased risk for metastasis. By leveraging these two technologies, we can identify patients who may qualify for clinical trials focused on treating metastatic disease. This approach can also lead to better overall survival for patients with uveal melanoma.” Given the high metastatic rate of SNMM and its dismal prognosis, it is of paramount importance to investigate potential diagnostic biomarkers for the early detection of SNMM with distant metastasis (SNMM-M) and identify therapeutic targets for individualized treatment.”
Mona Foth, PhD University of Utah
Dong Ren, MD, PhD The Regents of the University of California, Irvine
Amanda Zucker Oregon Health & Science University
11 • Stewardship Report
Made with FlippingBook Ebook Creator